Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism

Amir Bolandparvaz, Rian Harriman, Natalia Vapniarsky Arzi, Kenneth Alvarez, Zexi Zang, Judy Van De Water, Jamal S. Lewis

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Introduction: Autism Spectrum Disorder (ASD) comprises a range of developmental disorders diagnosed in early childhood, where their ability to communicate and interact are impaired. In the U.S., an estimated 1 in 59 children 1 is born with ASD and the economic burden is a staggering $268 billion per year 2 . Current therapies are post-symptomatic and include behavioral interventions or symptom-derived pharmacological treatments. Recently, the Van De Water group discovered that about a quarter of ASD cases are caused by maternal autoantibodies (autoAbs) that can hinder normal neurodevelopment in the fetus. Moreover, they elucidated the seven proteins targeted by these autoAbs in the fetal brain, including lactate dehydrogenase A and B (LDHA, LDHB) 3 . Herein, we aim to develop a System for Nanoparticle-based Autoantibody Retention and Entrapment (SNARE) prophylactic as a biomagnetic trap-for sequestration of disease-propagating Maternal Autoantibody-Related (MAR) autoAbs. Our central hypothesis is that upon intravenous injection, the iron oxide NPs surface-conjugated with autoantigens will circulate throughout the maternal vasculature, and specifically ligate MAR autoAbs, thereby limiting antibody (Ab) transport across the placenta and preventing MAR autism. Currently, investigative aims are to synthesize SNAREs, assess Ab binding capacity, cytotoxicity and immunogenicity in vitro, as well as determine in vivo distribution and maximum tolerated dose.

Original languageEnglish (US)
Title of host publicationSociety for Biomaterials Annual Meeting and Exposition 2019
Subtitle of host publicationThe Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
PublisherSociety for Biomaterials
Number of pages1
ISBN (Electronic)9781510883901
StatePublished - Jan 1 2019
Event42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States
Duration: Apr 3 2019Apr 6 2019

Publication series

NameTransactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
Volume40
ISSN (Print)1526-7547

Conference

Conference42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
CountryUnited States
CitySeattle
Period4/3/194/6/19

Fingerprint

Autistic Disorder
Autoantibodies
Nanoparticles
Mothers
Antibodies
SNARE Proteins
Aptitude
Maximum Tolerated Dose
Autoantigens
Cytotoxicity
Iron oxides
Intravenous Injections
Placenta
Brain
Fetus
Economics
Pharmacology
Proteins
Water
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biotechnology
  • Biomaterials
  • Materials Chemistry

Cite this

Bolandparvaz, A., Harriman, R., Vapniarsky Arzi, N., Alvarez, K., Zang, Z., De Water, J. V., & Lewis, J. S. (2019). Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40). Society for Biomaterials.

Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. / Bolandparvaz, Amir; Harriman, Rian; Vapniarsky Arzi, Natalia; Alvarez, Kenneth; Zang, Zexi; De Water, Judy Van; Lewis, Jamal S.

Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium; Vol. 40).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bolandparvaz, A, Harriman, R, Vapniarsky Arzi, N, Alvarez, K, Zang, Z, De Water, JV & Lewis, JS 2019, Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. in Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium, vol. 40, Society for Biomaterials, 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence, Seattle, United States, 4/3/19.
Bolandparvaz A, Harriman R, Vapniarsky Arzi N, Alvarez K, Zang Z, De Water JV et al. Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. In Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials. 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
Bolandparvaz, Amir ; Harriman, Rian ; Vapniarsky Arzi, Natalia ; Alvarez, Kenneth ; Zang, Zexi ; De Water, Judy Van ; Lewis, Jamal S. / Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism. Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting. Society for Biomaterials, 2019. (Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium).
@inproceedings{5314c110cf3c48bdb6e84d0a41f94606,
title = "Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism",
abstract = "Introduction: Autism Spectrum Disorder (ASD) comprises a range of developmental disorders diagnosed in early childhood, where their ability to communicate and interact are impaired. In the U.S., an estimated 1 in 59 children 1 is born with ASD and the economic burden is a staggering $268 billion per year 2 . Current therapies are post-symptomatic and include behavioral interventions or symptom-derived pharmacological treatments. Recently, the Van De Water group discovered that about a quarter of ASD cases are caused by maternal autoantibodies (autoAbs) that can hinder normal neurodevelopment in the fetus. Moreover, they elucidated the seven proteins targeted by these autoAbs in the fetal brain, including lactate dehydrogenase A and B (LDHA, LDHB) 3 . Herein, we aim to develop a System for Nanoparticle-based Autoantibody Retention and Entrapment (SNARE) prophylactic as a biomagnetic trap-for sequestration of disease-propagating Maternal Autoantibody-Related (MAR) autoAbs. Our central hypothesis is that upon intravenous injection, the iron oxide NPs surface-conjugated with autoantigens will circulate throughout the maternal vasculature, and specifically ligate MAR autoAbs, thereby limiting antibody (Ab) transport across the placenta and preventing MAR autism. Currently, investigative aims are to synthesize SNAREs, assess Ab binding capacity, cytotoxicity and immunogenicity in vitro, as well as determine in vivo distribution and maximum tolerated dose.",
author = "Amir Bolandparvaz and Rian Harriman and {Vapniarsky Arzi}, Natalia and Kenneth Alvarez and Zexi Zang and {De Water}, {Judy Van} and Lewis, {Jamal S.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
series = "Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium",
publisher = "Society for Biomaterials",
booktitle = "Society for Biomaterials Annual Meeting and Exposition 2019",

}

TY - GEN

T1 - Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism

AU - Bolandparvaz, Amir

AU - Harriman, Rian

AU - Vapniarsky Arzi, Natalia

AU - Alvarez, Kenneth

AU - Zang, Zexi

AU - De Water, Judy Van

AU - Lewis, Jamal S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Autism Spectrum Disorder (ASD) comprises a range of developmental disorders diagnosed in early childhood, where their ability to communicate and interact are impaired. In the U.S., an estimated 1 in 59 children 1 is born with ASD and the economic burden is a staggering $268 billion per year 2 . Current therapies are post-symptomatic and include behavioral interventions or symptom-derived pharmacological treatments. Recently, the Van De Water group discovered that about a quarter of ASD cases are caused by maternal autoantibodies (autoAbs) that can hinder normal neurodevelopment in the fetus. Moreover, they elucidated the seven proteins targeted by these autoAbs in the fetal brain, including lactate dehydrogenase A and B (LDHA, LDHB) 3 . Herein, we aim to develop a System for Nanoparticle-based Autoantibody Retention and Entrapment (SNARE) prophylactic as a biomagnetic trap-for sequestration of disease-propagating Maternal Autoantibody-Related (MAR) autoAbs. Our central hypothesis is that upon intravenous injection, the iron oxide NPs surface-conjugated with autoantigens will circulate throughout the maternal vasculature, and specifically ligate MAR autoAbs, thereby limiting antibody (Ab) transport across the placenta and preventing MAR autism. Currently, investigative aims are to synthesize SNAREs, assess Ab binding capacity, cytotoxicity and immunogenicity in vitro, as well as determine in vivo distribution and maximum tolerated dose.

AB - Introduction: Autism Spectrum Disorder (ASD) comprises a range of developmental disorders diagnosed in early childhood, where their ability to communicate and interact are impaired. In the U.S., an estimated 1 in 59 children 1 is born with ASD and the economic burden is a staggering $268 billion per year 2 . Current therapies are post-symptomatic and include behavioral interventions or symptom-derived pharmacological treatments. Recently, the Van De Water group discovered that about a quarter of ASD cases are caused by maternal autoantibodies (autoAbs) that can hinder normal neurodevelopment in the fetus. Moreover, they elucidated the seven proteins targeted by these autoAbs in the fetal brain, including lactate dehydrogenase A and B (LDHA, LDHB) 3 . Herein, we aim to develop a System for Nanoparticle-based Autoantibody Retention and Entrapment (SNARE) prophylactic as a biomagnetic trap-for sequestration of disease-propagating Maternal Autoantibody-Related (MAR) autoAbs. Our central hypothesis is that upon intravenous injection, the iron oxide NPs surface-conjugated with autoantigens will circulate throughout the maternal vasculature, and specifically ligate MAR autoAbs, thereby limiting antibody (Ab) transport across the placenta and preventing MAR autism. Currently, investigative aims are to synthesize SNAREs, assess Ab binding capacity, cytotoxicity and immunogenicity in vitro, as well as determine in vivo distribution and maximum tolerated dose.

UR - http://www.scopus.com/inward/record.url?scp=85065430210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065430210&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:85065430210

T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium

BT - Society for Biomaterials Annual Meeting and Exposition 2019

PB - Society for Biomaterials

ER -